UnknownNot Applicable

Clinical and Molecular Study With Digital Support of Patients With Inoperable Lung Cancer

Greece200 participantsStarted 2022-03-23

Plain-language summary

The purpose of this study is to provide high quality oncology services to patients with inoperable Non-Small Cell Lung Cancer (NSCLC) in Greece. These services will be based on 3 pillars: 1. Clinical: personalized treatment will be administered and its effectiveness and safety will be recorded and evaluated. 2. Molecular: the gene footprint of each patient at the beginning of his treatment, the molecular identity of his tumor will be analyzed and recorded based on analysis with modern Next Generation Sequencing (NGS) techniques. 3. Digital: Patients will have access to the digital platform where they will record the adverse reactions they will face during their treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with non-small cell lung cancer stage IV * No younger than 18 years old patients * Performance status: 0-2 * Existence of biological material for the molecular analysis * Patients who have not been treated with any other treatment than adjuvant * Ability to use a mobile device or computer for digital communication Exclusion Criteria: * Childbearing women * Patients with PS \> 3 * Limited ability to use a mobile device for basic digital communication

What they're measuring

Molecular identification of patients with non-small cell lung cancer

Timeframe: up to 36 months

Trial details

NCT IDNCT05372081

SponsorHellenic Cooperative Oncology Group

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-09

Contact for this trial

Paris Kosmidis, MD

+30 210 6867105 parkosmi@otenet.gr

View on ClinicalTrials.gov More Non-Small Cell Carcinoma of Lung, TNM Stage 4 trials